Arrowhead Pharmaceuticals

---

source: coverage-next-full ticker: ARWR step: 01 title: Business Model & Overview date: 2026-06-09

Step 01 — Business Model & Overview: Arrowhead Pharmaceuticals (ARWR)

1. Executive Summary

Arrowhead Pharmaceuticals is a clinical-stage/early-commercial biopharmaceutical company that develops targeted RNA interference (RNAi) therapeutics using its proprietary TRiM™ (Targeted RNAi Molecule) platform. The company transitioned from a pure research/licensing revenue model to a commercial-stage company on November 18, 2025 when plozasiran (REDEMPLO) received FDA approval for familial chylomicronemia syndrome (FCS). [S1]

The business model has two intertwined value streams: (1) platform licensing — monetizing TRiM through large upfront deals with Sarepta Therapeutics, Novartis, Takeda, GSK, and Amgen; and (2) proprietary commercial products — building direct product revenue starting with REDEMPLO. These streams are structurally different: licensing creates large, episodic cash inflows that mask the underlying cost burn, while product revenue will grow more slowly but create a durable, recurring revenue base.

---

2. Technology Platform: TRiM™

What it is: TRiM (Targeted RNAi Molecule) is Arrowhead's modular siRNA delivery platform. It consists of three linked components: [S1]

1. Targeting ligand — routes the drug to a specific cell type (e.g., GalNAc for liver hepatocytes, proprietary ligands for lung epithelium, neurons)
2. Linker — connects targeting ligand to payload; enables tissue specificity tuning
3. siRNA payload — double-stranded RNA that silences a specific target gene through the endogenous RISC machinery

How it differs from Alnylam's GalNAc platform: TRiM is designed to be modular — the targeting ligand can theoretically be swapped to redirect the drug to non-hepatic tissues. This is the basis for Arrowhead's extra-hepatic programs in lung (ARO-RAGE inhaled), CNS (ARO-MAPT, ARO-HTT), and muscle (ARO-DUX4, partnered with Sarepta). Alnylam's GalNAc platform is primarily hepatic; it uses LNP delivery for some non-hepatic programs, which requires IV infusion rather than subcutaneous injection. [S2]

Subcutaneous delivery: All TRiM-based programs are delivered via subcutaneous injection, typically quarterly or semi-annually. This is a major commercial advantage vs. IV infusion (reduces hospital visits, increases patient compliance). [S2]

---

3. Value Chain Layer Map

Discovery Layer (Internal)
├── Target identification (genetics-validated targets)
├── siRNA sequence optimization
└── TRiM molecule assembly (ligand + linker + siRNA)
          ↓
Development Layer
├── IND-enabling studies / Phase 1 safety
├── Phase 2 proof-of-concept
├── Phase 3 pivotal (PALISADE, SEQUOIA, etc.)
└── Regulatory filing (NDA/BLA with FDA)
          ↓
Commercialization Layer
├── Proprietary (REDEMPLO): Arrowhead-owned US commercial team
│   └── Orphan pricing; KOL-driven FCS market
└── Partnered: Sarepta (rare muscle), Takeda (fazirsiran liver), GSK (HBV/MASH), Amgen (Lp(a))
          ↓
Manufacturing Layer
├── San Diego, CA — research manufacturing
├── Madison, WI — clinical supply
└── Verona, WI — commercial-scale facility (160,000 sq ft, operational 2025)
          ↓
Value Capture
├── Upfront licensing fees (Sarepta $825M, Novartis $200M, etc.)
├── Milestone payments (tied to clinical and commercial events)
├── Royalties (on partner product sales)
└── Direct product revenue (REDEMPLO — FCS launch, sHTG pending)

---

4. Revenue Architecture

Arrowhead generates revenue through four mechanisms, with very different risk and timing profiles:

Revenue Type	Example	Timing	Predictability
Upfront licensing	Sarepta $825M (Q2 FY2025), Novartis $200M (FY2025), GSK $120M (FY2022)	Episodic; deal-closure dependent	Low
Clinical milestones	Payments when partner's drug enters Phase 2, 3, etc.	Lumpy; clinical progress dependent	Low-Medium
Regulatory/Commercial milestones	NDA submission, FDA approval, first sale	Binary events	Low-Medium
Product royalties	Olpasiran (Amgen) royalties sold to Royalty Pharma (2022)	Recurring but Royalty Pharma owns them	N/A for ARWR
Direct product revenue	REDEMPLO FCS sales (from Nov 2025)	Recurring; growing slowly	Medium (small market)

Structural insight: The episodic nature of upfront payments creates high revenue volatility — $3.6M in FY2024 vs. $829.4M in FY2025, both legitimate years. The correct way to think about Arrowhead's cash flow is: underlying R&D burn (~$688M/year) ± large episodic cash inflows from deals. Product revenue from REDEMPLO will eventually smooth this, but FCS is an ultra-rare disease (~3,000 US patients) so peak product revenue is likely below $100M/year for FCS-only. [S3]

---

5. Business Segments

Arrowhead operates as a single reportable segment (research and development of RNAi therapeutics). The company does not break out revenue by product in detail (it is all collaboration/license revenue under ASC 606). [S1]

De facto portfolio structure:

1. Proprietary commercial assets: Plozasiran (FCS — launched; sHTG — Phase 3, data Q3 2026); zodasiran (ANGPTL3 — Phase 2/3)
2. Co-development assets (Takeda): Fazirsiran (AATD — Phase 3); 50/50 US co-commercialization; 20-25% ex-US royalties
3. Out-licensed assets (Sarepta): ARO-DUX4/ARO-MYOD (muscular dystrophy); ARO-LGI1 and others under $825M deal
4. Out-licensed assets (GSK): HSD17B13 (MASH, Phase 3); HBV daplusiran (Phase 2)
5. Out-licensed assets (Amgen): Olpasiran (Lp(a), Phase 3 — Amgen wholly responsible; royalties sold to Royalty Pharma)
6. Discovery/early clinical: ARO-INHBE (obesity/MASH), ARO-RAGE (COPD), ARO-C3 (IgAN), ARO-MAPT (Alzheimer's), ARO-HTT (Huntington's), ARO-SOD1 (ALS)

---

6. Competitive Positioning (Brief)

The RNAi space is oligopolistic. Alnylam holds ~45% market share with 5 approved drugs; ARWR is the newest commercial entrant. Arrowhead's differentiation rests on:

1. Extra-hepatic delivery — lung, CNS, muscle programs not replicable with GalNAc alone
2. Cardiometabolic breadth — plozasiran (ApoC-III), zodasiran (ANGPTL3), olpasiran (Lp(a) via Amgen), ARO-DIMER (PCSK9+ApoC-III simultaneous)
3. Platform modularity — TRiM's ligand-swap architecture enables rapid new program starts
4. Wisconsin manufacturing facility — vertical integration reduces reliance on CMOs at scale [S2]

---

7. Key Risks (Overview)

1. Clinical binary risk: Phase 3 failure in sHTG (plozasiran PALISADE) would remove the largest commercial opportunity
2. Balance sheet stress: $1.37B debt (Q2 FY2026) vs. declining cash reserves after FY2025 windfall
3. Commercial execution: First commercial launch with a new team in an ultra-rare disease is notoriously difficult; physicians are unfamiliar with FCS diagnosis
4. Competition from Alnylam: Superior commercial infrastructure and scale; potential ANGPTL3 program overlap
5. R&D spend acceleration: R&D growing ~20-43% per year with no clear ceiling as pipeline expands

---

8. Source Index

[S1] SEC EDGAR 10-K FY2024 summary — ARWR_financials/sec_filings/10K_FY2024_summary.md [S2] ARWR Competitive Landscape — ARWR_financials/industry/competitive_landscape.md [S3] StockAnalysis.com financial summary — ARWR_financials/other/stockanalysis_summary.md [S4] Consensus and market data — ARWR_financials/other/consensus.md

---

source: coverage-next-full ticker: ARWR step: 04 title: Financial Quality & Adversarial Research Sweep date: 2026-06-09

Step 04 — Financial Quality & Adversarial Research Sweep: Arrowhead Pharmaceuticals (ARWR)

1. Statement-Quality Assessment

Income Statement Quality

Revenue recognition under ASC 606: The single most important quality issue for ARWR's income statement is the episodic, large-lump recognition of collaboration and license revenue. Arrowhead accounts for performance obligations in collaboration agreements and recognizes upfronts over the performance period. [S1]

Key quality issues to note:

• FY2025 Q2 ($542.7M in one quarter): The Sarepta deal ($825M+ upfront) creates a one-time revenue spike that is NOT a proxy for run-rate cash generation. Reported FY2025 revenue of $829.4M and operating income of $98.4M are not indicative of sustainable profitability.
• Deferred revenue dynamics: Large upfronts create deferred revenue on the balance sheet; as obligations are satisfied, deferred revenue converts to income. This creates a potential GAAP income stream that doesn't correspond to cash received in the same period. At FY2024, deferred revenue from collaborations was ~$103.2M current + $845.6M noncurrent. [S1]
• R&D expense: all internal R&D is expensed — no capitalization of drug development costs under US GAAP (they treat FDA approval as the first point where technological feasibility is established). This understates asset value but is standard practice.

Operating expense quality:

• R&D expense is the most reliable metric: $607M FY2025, growing ~20% YoY. Breakdowns suggest genuine platform expansion, not padding.
• G&A jumped to $123.9M FY2025 vs. $98.8M FY2024 (+25%) — reflects commercial infrastructure build-up post-plozasiran NDA. G&A as % of R&D is ~20%, reasonable for a company transitioning to commercial stage.
• SBC: declining from $120.9M (FY2022 peak) to $63.4M (FY2025) — positive signal of cost discipline; SBC as % of total revenue was 7.6% in FY2025 vs. inflated in prior years.

Adjustments recommended:

1. Normalize revenue to deal-adjusted basis: strip out one-time upfronts, focus on milestone cadence and product revenue run-rate
2. Cash-basis P&L: Operating cash flow is more informative than GAAP net income for ARWR; FY2025 OCF of $179.6M (positive) vs. FY2024 ($462.9M) (deeply negative)
3. Exclude non-cash SBC from EBITDA-like metrics — though SBC is real dilution, it inflates reported OpEx vs. cash burn

Balance Sheet Quality

Total debt build:

• FY2021: $25.5M (near debt-free)
• FY2022: $81.6M (convertible notes)
• FY2023: $383.5M (Royalty Pharma royalty liability + convertibles)
• FY2024: $851.9M ($400M Sixth Street term loan + Royalty Pharma + convertibles)
• FY2025: $733.7M (some repayment/reclassification)
• Q2 FY2026: $1,373M (major new financing — likely new convertible notes)

Royalty liability complexity: In November 2022, Arrowhead sold its royalty rights on olpasiran (Amgen's Lp(a) drug) to Royalty Pharma for $250M upfront, structured as a non-recourse royalty purchase that is classified as debt on Arrowhead's balance sheet under US GAAP. This is a real liability if olpasiran royalties are sufficient to repay it, but it is effectively contingent on Amgen's clinical success. [S1]

Sixth Street term loan ($400M drawn, Sep 2024):

• 7-year term, secured by all ARWR assets
• Interest rate ~9–10% (estimated based on prevailing lending terms for clinical-stage biotechs)
• Annual interest expense: ~$36–40M (material cash cost)
• Covenant risk: If clinical programs fail and the company cannot service the debt, this could be a significant distress risk

Equity quality:

• Stockholders' equity: $466.1M (FY2025); recovered from near-wipe-out level of $56M in Q1 FY2025
• Book value is largely intangible in practice — most of ARWR's value is in its pipeline IP, not on the balance sheet
• Accumulated deficit at FY2025: Very large (>$2B accumulated losses since inception) — standard for clinical-stage biotech

Cash quality:

• FY2025: $88.7M cash + $692.4M short-term investments = $781M liquid
• Q2 FY2026: $147.5M cash (ST investments not separately broken out at Q2 FY2026) — may have been deployed or reclassified
• Q2 FY2026 total assets jumped to $2,268M (from $1,385M at FY2025) — new debt raises likely went to the balance sheet as cash/investments

Cash Flow Statement Quality

• Operating cash flow is the most reliable signal — it removes deferred revenue and non-cash items
• Q2 FY2026 OCF: $84.4M (positive, suggests Q2 had net cash inflows); Q1 FY2026: $13.5M (positive)
• FY2025 cumulative quarterly OCF: $460M (Q2 FY2025 large receipt) + ($154.7M) + ($146.3M) + $20.5M = $179.5M for the year
• CapEx has normalized to ~$2–8M/quarter in FY2026 after the facility build ($141–177M/year in FY2023–FY2024)

---

2. Adversarial Research Sweep

Note: No earnings transcripts available on this research path. Adversarial concerns are sourced from SEC filings (10-K risk factors), press coverage, proxy analysis, and insider transaction data.

Issue 1: Say-On-Pay Failure at 2026 Annual Meeting

What happened: At the March 19, 2026 Annual Meeting, say-on-pay vote FAILED with 59% of votes cast AGAINST management compensation. 41.6M shares voted FOR, 59.9M shares voted AGAINST — a significant shareholder rebellion. [S3]

Why it matters:

• CEO Christopher Anzalone received $9.0M total compensation in FY2025, with $6.8M in RSU grants
• The compensation committee's lead (Michael Perry) received only 69% shareholder support — the lowest of any director
• A new equity plan authorizing 10.5M additional shares was approved (overhang increasing from 5.6% to 11.8% of shares outstanding)
• Say-on-pay failures are rare and signal deep investor dissatisfaction with governance

Analysis: The combination of (a) CEO dual role as Chairman + CEO (no independent chair), (b) large equity grants in a year with near-zero product revenue (FY2024 was a trough year), and (c) the 10.5M share equity plan authorization — totaling ~7.5% dilution — appears to have crystalized shareholder frustration.

Governance red flag severity: MEDIUM-HIGH. This does not impair the scientific thesis but it signals a management-shareholder alignment problem that could lead to further governance changes, compensation restructuring, or activist involvement.

Issue 2: CEO and Insider Selling

What happened: CEO Anzalone sold approximately 347,055 shares in December 2025 (~$23.1M at $64–69/share). Multiple directors also sold in the same December 2025 window. Estimated total insider sales over 12 months (Sep 2025–May 2026): $37–40M. [S3]

Analysis: December 2025 window (6 weeks post-FDA approval in November 2025) was the first open trading window after the approval catalyst. Selling post-approval is standard for executives who have been holding through the development period and is covered under 10b5-1 plans. However:

• The timing (peak price window) and scale ($23M single executive) is aggressive
• New CFO Daniel Apel (joined May 2025) also sold $934K (April 2026) and filed Form 144 for an additional 100,000 shares
• CEO's sale of 347K shares represents ~0.25% of shares outstanding — not a catastrophic signal but notable

Red flag severity: MEDIUM. No insider buying visible. Selling clusters are a caution signal but not a definitive thesis killer.

Issue 3: Debt Load and Runway

What happened: Total debt rose from near-zero ($25.5M in FY2021) to $1,373M by Q2 FY2026. [S2]

Components:

• Royalty Pharma liability (~$250M, related to olpasiran royalty sale — non-recourse per Amgen clinical success)
• Sixth Street term loan ($400M, drawn Sep 2024; 7-year, secured)
• Convertible notes (likely new tranche in Q2 FY2026 given asset jump from $1.4B to $2.3B)

Cash analysis: If Q2 FY2026 total assets jumped $883M ($1,385M → $2,268M) and total debt jumped $639M ($733M → $1,373M), the new debt is likely mostly on the balance sheet as liquid assets (~$640M net inflow). This suggests ARWR raised a large convertible note tranche in Q1 or Q2 FY2026, adding meaningful runway.

Revised liquid assets estimate (Q2 FY2026): ~$147.5M reported cash + ~$640M estimated ST investments from new raise = ~$787M liquid

At ~$215–223M/quarter burn, current liquidity covers approximately 3.5 years without any additional revenue — comfortable for a company with multiple Phase 3 programs expected to read out in 2026–2027.

Red flag severity: LOW-MEDIUM. Debt is elevated but appears manageable given large liquid assets and ongoing deal flow. Risk escalates if Phase 3 programs fail and no new deals materialize.

Issue 4: R&D Burn Acceleration

What happened: Quarterly R&D jumped from $133–137M in early FY2025 to $177M in Q1 FY2026 (+30% YoY). G&A jumped from $26.9M to $46.0M (+71% YoY) in Q1 FY2026 vs. Q1 FY2025. [S2]

Analysis: The G&A spike is directly attributable to REDEMPLO commercial infrastructure (commercial team, sales force, patient access programs). R&D acceleration reflects pipeline advancement with 6 Phase 3 programs running simultaneously. Both are "good" spending increases in the context of pipeline/commercial advancement, but they increase the burn rate significantly.

Red flag severity: LOW. Accelerating spend is expected; concern would arise only if burn rate exceeds runway.

Issue 5: No Product Revenue Track Record

What happened: Arrowhead generated no product revenue through FY2024. REDEMPLO launched November 2025.

Analysis: The company has never built or operated a commercial infrastructure. FCS is an ultra-rare disease requiring unusual diagnostic steps (patients often go years without a diagnosis). The commercial team is being assembled from scratch. 400+ prescriptions in the first commercial quarter is an early positive signal, but it's too early to conclude commercial execution is proven.

Red flag severity: MEDIUM. Commercial execution risk is real but manageable; FCS is a "practice" market for the larger sHTG opportunity.

---

3. Financial Quality Score

Dimension	Score	Notes
Revenue quality	3/10	Highly episodic; deal-dependent; not comparable YoY
Earnings quality	3/10	GAAP earnings completely dominated by deal timing
Cash flow quality	7/10	OCF is more reliable; normalize for deal receipt timing
Balance sheet quality	5/10	Assets clean; liabilities complex (Royalty Pharma, term loan, converts)
Governance quality	4/10	CEO/Chair dual role; say-on-pay failure; aggressive insider selling
Disclosure quality	8/10	10-K disclosures are comprehensive; pipeline updates are detailed

---

4. Source Index

[S1] XBRL Financial Summary + 10-K FY2024 — ARWR_financials/xbrl/ + sec_filings/ [S2] StockAnalysis Financial Summary — ARWR_financials/other/stockanalysis_summary.md [S3] Governance + Insider Transactions — ARWR_financials/proxy/ [S4] Consensus & News — ARWR_financials/other/consensus.md

---

source: coverage-next-full ticker: ARWR step: 12 title: Bull vs. Bear — Analyst Debate date: 2026-06-09

Step 12 — Bull vs. Bear: Arrowhead Pharmaceuticals (ARWR)

Note: Earnings transcripts were not used in this research path. The bull/bear debate is inferred from consensus notes, press releases, filings, and recent news coverage.

1. Street Consensus Snapshot (June 2026)

• 9 Buy / Strong Buy | 4 Hold | 0 Sell (out of ~13 analysts)
• Average price target: $88.17 (+19.4% upside from $73.86)
• Range: $46 (low) – $110 (Piper Sandler)
• Most recent upgrade: Morgan Stanley → Overweight, $100 PT (April 21, 2026)
• Notable neutral: Goldman Sachs (Neutral; no PT in available data)

The Street is predominantly bullish. The 4 Holds and wide PT range ($46–$110) reflect genuine uncertainty about (a) plozasiran sHTG Phase 3 outcome and (b) long-term revenue model post-milestone-windfall normalization. [S4]

---

2. Bull Case — Core Arguments

Bull Argument 1: plozasiran sHTG is a Blockbuster in Waiting

Bull thesis: PALISADE/SHASTA-3/MUIR-3 Phase 3 data expected Q3 2026 will be positive, and plozasiran will be approved for severe hypertriglyceridemia — a 600,000-patient US market with no other FDA-approved drug. At orphan-like pricing ($150,000–200,000/year) and 10-20% penetration, this is a $1.5–2.5B+ peak annual revenue opportunity. Given REDEMPLO already showed -80% TG reduction in Phase 3 FCS, and the same mechanism applies in sHTG, the probability of success is higher than a typical Phase 3. The market is not fully pricing this in at current valuations.

Supporting evidence:

• Phase 3 PALISADE FCS data showed -80% TG reduction at Week 26 — the endpoint was convincingly met
• The sHTG indication uses the same mechanism; only the patient population is broader
• Analysts characterize the sHTG opportunity as a "$4B REDEMPLO opportunity" [S4]
• Competitive moat in sHTG is strong — Waylivra was FDA-rejected; no approved US alternative

Bull Argument 2: ARO-INHBE Obesity Creates a Platform Re-rating Catalyst

Bull thesis: ARO-INHBE's EASL 2026 data showing ~2x weight loss vs. tirzepatide alone when co-administered is a potential blockbuster signal. The obesity market is the fastest-growing drug market globally ($40B+). If INHBE works as a GLP-1 potentiator, it could be partnered for $1B+ upfront (analogous to the Sarepta deal scale) OR become ARWR's own blockbuster. The bull camp argues this asset is underappreciated and could trigger a re-rating of the platform at a multiple more like a dual-platform biotech (RNAi + metabolic disease).

Supporting evidence:

• Phase 1/2a data at EASL 2026: ~-9.4% weight loss at Week 16 (combo with tirzepatide) vs. ~-4.8% tirzepatide alone
• INHBE is genetically validated: INHBE loss-of-function carriers have reduced body mass and fat — strong biological rationale
• No RNAi competitor has a validated obesity asset in clinical trials
• Novo Nordisk (GLP-1 leader) is a natural partner — could pay large upfront for combo strategy [S3]

Bull Argument 3: TRiM Platform at Alnylam-Equivalent Value with Greater Optionality

Bull thesis: At $10.4B market cap vs. Alnylam at $25B+, Arrowhead trades at a significant discount despite having 20+ clinical programs, one approved product, six Phase 3 programs, and arguably the broadest non-hepatic RNAi pipeline in the industry. If ARWR reaches $3B in annual revenue by 2030 (plozasiran FCS+sHTG + fazirsiran + zodasiran + deal milestones), the stock should trade at 8–10x revenue = $24–30B+ market cap — 2.3x–2.9x upside from current.

Supporting evidence:

• Alnylam trades at ~8x FY2026E revenue ($25B MC / ~$3.2B FY2026E rev)
• ARWR at $10.4B trades at ~21x FY2026E revenue ($444M est.) — appears expensive, but the revenue estimate is depressed; FY2030 revenue potential is $2–3B
• Big Pharma has valued Arrowhead's pipeline at >$12B in total deal economics (Sarepta $10B+ + Novartis large + Takeda large + GSK large + Amgen olpasiran milestones) — confirming external pipeline value validation [S1]

---

3. Bear Case — Core Arguments

Bear Argument 1: sHTG Phase 3 Failure Would Devastate the Stock

Bear thesis: The stock at $73.86 reflects significant optimism about plozasiran sHTG approval. If Phase 3 data disappoints — either primary endpoint miss or unacceptable safety signal — the stock could fall 40–60% (to $30–45). The FCS-only commercial story is too small (~$100–300M peak revenue) to justify a $10.4B enterprise value. The sHTG bet is binary and the outcome is uncertain.

Supporting evidence:

• Phase 3 always has ~30–35% failure probability regardless of Phase 2 success (industry base rate)
• The sHTG patient population is heterogeneous — different underlying metabolic drivers could dilute the ApoC-III knockdown efficacy
• Competing therapies (fibrates, omega-3s) are cheap and widely used — payers may demand large discounts even if REDEMPLO is approved for sHTG
• The $46 bear case price target (from the analyst community) implies ~38% downside from current [S4]

Bear Argument 2: Governance Concerns Signal Misalignment

Bear thesis: The say-on-pay failure (59% against management), combined with ~$37–40M in insider selling over 12 months, and the new equity plan adding 10.5M shares (7.5% dilution) are all signs that management incentives are not aligned with shareholders. If governance activism escalates (ISS campaign, activist investor), management distraction could delay clinical programs or lead to a governance overhaul at a critical juncture (2026 Phase 3 readouts).

Supporting evidence:

• Say-on-pay failures at 59% are rare and typically precede either compensation redesign or activist involvement
• CEO/Chair duality is a structural governance weakness
• New CFO selling within months of joining is unusual
• The existing equity plan already authorizes shares that could dilute existing holders by 10%+ [S2]

Bear Argument 3: Balance Sheet Leverage and Burn Rate Create Dilution Risk

Bear thesis: ARWR has $1.37B in debt, an estimated ~$860–890M annual burn rate, and ~$787M in estimated liquid assets. Without a new deal in FY2027, the company will need to raise capital again — likely through equity at some price. Given the stock has already re-rated 5x from the trough, any new equity raise at $60–75 would be highly dilutive on a per-share basis. The company could need to dilute shareholders by 20–30% to fund operations through FY2028.

Supporting evidence:

• FY2026 consensus revenue ~$444M vs. ~$860–890M annual burn → net cash outflow ~$415–445M in FY2026 if no new deals
• Q2 FY2026 positive OCF ($84.4M) was partly driven by deal milestones; underlying product revenue cannot cover the burn
• Total debt at $1,373M creates ~$55–72M/year in cash interest payments
• Oct 2023 equity raise at $28.50 shows management will dilute shareholders when needed [S1]

---

4. Bull Case — 3 Bullets

1. sHTG Phase 3 success unlocks a $1.5–4B peak revenue opportunity — REDEMPLO in severe hypertriglyceridemia (600,000 US patients) would be the first FDA-approved drug for this indication; Phase 3 data in Q3 2026 is the defining binary; plozasiran's FCS efficacy (-80% TG) supports high conviction in Phase 3 outcome.

2. ARO-INHBE obesity/MASH data is an underappreciated platform optionality — EASL 2026 Phase 1/2a showing ~2x weight loss improvement vs. tirzepatide alone positions ARWR as a GLP-1 potentiator with no RNAi competitor; a partnership deal analogous to Sarepta ($1B+ upfront) is plausible and not priced in.

3. TRiM platform is valued at a material discount to Alnylam despite comparable pipeline breadth — ARWR's 20+ programs and 6 Phase 3 assets, with $12B+ in validated partnership economics, represent Alnylam-equivalent pipeline depth at a 60%+ discount to Alnylam's market cap; successful Phase 3 readouts in 2026–2028 should close this gap.

---

5. Bear Case — 3 Bullets

1. sHTG Phase 3 failure would collapse the commercial thesis — ~$8B+ of the $10.4B market cap is pipeline optionality beyond FCS; a Phase 3 miss in sHTG (30-35% probability) removes the largest near-term revenue opportunity and could send the stock back to the $30–45 range.

2. Governance and insider selling signal management-shareholder misalignment — Say-on-pay failure (59% against), CEO/Chairman duality, $37–40M of insider selling in 12 months, and new equity plan adding 7.5% dilution collectively create a governance risk that could escalate at the worst possible time (during critical 2026 Phase 3 readouts).

3. Leverage + burn rate creates a dilution trap — At ~$860–890M annual burn rate vs. ~$444M FY2026E revenue, the company faces a structural cash deficit that requires new deals or equity raises annually; with $1.37B in debt and $787M in liquid assets, the runway is ~3.5 years but only if deal flow materializes; failure to close new partnerships in FY2027 triggers a dilutive equity raise.

---

6. Source Index

[S1] StockAnalysis + XBRL Financial Summary — ARWR_financials/ [S2] Governance/Proxy — ARWR_financials/proxy/ [S3] Investor Presentation — ARWR_financials/presentations/ [S4] Consensus & Market Data — ARWR_financials/other/consensus.md